Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”

Check out here for more.
Find more posts on Hemostasis Today.
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!
